Anthropic just released Claude Fable 5, calling it the most powerful AI model it has ever made widely available and praising its skills in biology, among others. But the model won’t answer basic biology questions — the kind you’d expect a high schooler to handle. Instead, it hands off the query to the former flagship model, Claude Opus 4.8.
It isn’t because Fable doesn’t know the answers. It’s because Anthropic won’t let it, by design.
Fable is a public-facing, Mythos-class model, a family so capable at cybersecurity tasks Anthropic said it was too dangerous to release publicly. But while Anthropic has spent much of the extended Mythos rollout warning about cybersecurity, it is biology where Fable’s guardrails are the most obvious — and most limiting.
When I tried the model, it refused to answer a range of basic biology questions, many that felt about as far away from any plausible safety risk as any question could be. It would not respond to “tell me about cell membranes” or answer “what are mitochondria,” that famous powerhouse of the cell. It refused to explain “what is a prion,” the proteinaceous particles behind mad cow disease, or “how mRNA vaccines work.”
“We made this tradeoff so customers could benefit from the model’s capabilities sooner without the risks.”
The restrictions applied to ordinary and objectively rather harmless medical queries too. Fable would not answer “what causes hay fever,” explain how asthma medicine works, explain how antibiotic resistance arises, or tell me what Ebola is and how it spreads. Some of my basic queries occasionally got through, with Fable answering questions like “what is cancer” and “what is DNA.” When Fable refused, Opus 4.8 generally answered perfectly well.
Anthropic says the broad biology filters are an intentional choice and are deliberately conservative, with bioweapons the primary concern. “With the launch of Claude Fable 5, our first Mythos-class model, we believe models now have a greater ability to accomplish real-world scientific tasks and for malicious actors to potentially use our models for highly risky biological research,” spokesperson Paruul Maheshwary told noti.group. “We have always used classifiers to block our models from helping with bioweapons-related requests. To deploy Fable 5 safely, we believe it was necessary to be overly conservative with our safeguards so they block most queries tied to biology work.”
Anthropic has previously highlighted four key areas where it would throttle Fable’s responses for safety: chemistry, biology, cybersecurity, and distillation, a technique for training smaller AIs using the outputs of larger ones. The company has accused Chinese rivals like DeepSeek of using distillation on its models on an “industrial” scale.
While I could not meaningfully test distillation, Fable seemed more willing to answer questions about chemistry and cybersecurity. For example, it gave a basic overview of the explosive TNT, though withheld synthesis instructions “for obvious reasons.” It readily answered questions on the use of chlorine gas as a chemical weapon, common password threats, and nuclear fusion and fission, as well as explaining how to secure an iPhone from hackers. It still limits: Fable deferred to Opus when I asked it about sarin gas, a highly toxic nerve agent. Fable and Opus both refused the prompt “how to make anthrax,” and Claude paused the chat entirely. That made sense. The mitochondria prompt refusal seems like a false positive.
“We made this tradeoff so customers could benefit from the model’s capabilities sooner without the risks,” Maheshwary explained, adding that Anthropic is working hard to improve its detection and reduce the false positives. “We intend to make Mythos-class models available without these safeguards to the broader biology and life sciences community so these capabilities can be used to accelerate biomedical research and drug discovery.”
Anthropic did not answer questions about whether this kind of restricted release will become the new norm for future models.
[Notigroup Newsroom in collaboration with other media outlets, with information from the following sources]
